Targeting signal transducer and activator of transcription signaling pathway in leukemias.
about
Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cellsPIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancersTargeting the innate immune system as immunotherapy for acute myeloid leukemiaPush and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity.Therapeutic modulators of STAT signalling for human diseasesKaempherol and Luteolin Decrease Claudin-2 Expression Mediated by Inhibition of STAT3 in Lung Adenocarcinoma A549 Cells.A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translationTLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivoMyeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases.The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition.MEK/ERK dependent activation of STAT1 mediates dasatinib-induced differentiation of acute myeloid leukemia.STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancersPhase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemiaLoss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor SurveillanceMechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia.Sphingolipid signaling and hematopoietic malignancies: to the rheostat and beyond.Novel mechanism for Fc{epsilon}RI-mediated signal transducer and activator of transcription 5 (STAT5) tyrosine phosphorylation and the selective influence of STAT5B over mast cell cytokine production.Dietary compounds as potent inhibitors of the signal transducers and activators of transcription (STAT) 3 regulatory network.Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cellsBlockade of glioma proliferation through allosteric inhibition of JAK2.Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.The HER2 inhibitor TAK165 Sensitizes Human Acute Myeloid Leukemia Cells to Retinoic Acid-Induced Myeloid Differentiation by activating MEK/ERK mediated RARα/STAT1 axis.STAT5 outcompetes STAT3 to regulate the expression of the oncogenic transcriptional modulator BCL6.Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity.The erythropoietin receptor: molecular structure and hematopoietic signaling pathways.STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application.STAT3 inhibitors: finding a home in lymphoma and leukemia.Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3)Matrine suppresses cell growth of human chronic myeloid leukemia cells via its inhibition of the interleukin-6/Janus activated kinase/signal transducer and activator of transcription 3 signaling cohort.Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2.Inactivation of HDAC3 and STAT3 is critically involved in 1-stearoyl-sn-glycero-3-phosphocholine-induced apoptosis in chronic myelogenous leukemia K562 cells.Repression of STAT3, STAT5A, and STAT5B expressions in chronic myelogenous leukemia cell line K-562 with unmodified or chemically modified siRNAs and induction of apoptosis.Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance.The cdk5 kinase regulates the STAT3 transcription factor to prevent DNA damage upon topoisomerase I inhibition.Curcumin analogue, A13, exhibits anti-leukemia effect via inhibiting STAT3.Suppression of STAT5A and STAT5B chronic myeloid leukemia cells via siRNA and antisense-oligonucleotide applications with the induction of apoptosis.Role of human herpesvirus 8 interleukin-6-activated gp130 signal transducer in primary effusion lymphoma cell growth and viability.Matrix Metalloproteinase-9 Production by Immortalized Human Chondrocyte Lines.
P2860
Q24313261-16AC83A0-D085-471A-AF38-DEB6A708B040Q24603099-C6CE2C44-E10E-4FF4-9DE6-9410B4A41D6EQ27015876-E02A0DA5-5816-4237-891E-CF9F7AC27E51Q33553545-6C774A57-82A8-46F4-B75F-E46A79F50214Q33684732-15722215-0700-4078-BD65-DD034EDDC5FCQ33852030-C47CDE85-3816-494A-BB6E-BA9722E46A0EQ33934987-C67881AC-9CEC-4E93-9844-FDCFBA3A1CCCQ34320769-9791EB63-F9B3-411F-9393-E38E5A6BC575Q34474214-6B74C102-DE91-4805-8105-37E80C105301Q34484344-F948BDE7-1A73-40DA-816B-4AE73B1701DEQ34794431-AFDC9BEA-749B-4F46-BE5F-E4F901FB398DQ34796500-B4C2262D-74CE-45E4-8BCB-D26AF2A84BD9Q35085867-ECC99F6F-C91E-4864-AA0C-F195BED50CF5Q35086418-630A9D7E-ED6E-4754-8AFD-DB1B9B983D56Q35125923-E18D8283-D8C4-4582-ABE4-A2BD49623892Q35545492-2DC72732-77A4-465A-B446-4518678F09FCQ35675184-2DD0AE89-5B2C-4306-A33C-1EDDB21CE345Q35694030-24B729CC-1312-456E-B4EA-E7A627DC156CQ35863370-3E1D9220-B4C1-4AF5-BE79-14D62B8332BFQ36214610-A984FBF8-C5A2-4EE6-A1FE-7E677F235ED0Q36633592-288AD2A7-0F14-4439-A21F-F3FF1641E517Q36755491-74466817-FAF1-42FA-8ACF-BB540BA9FF16Q36796264-0DAB8D4D-01B1-4319-ADA4-3313A7898EC7Q37036322-7AF1EFF9-9C73-44F7-A37F-8CEFBD0F9E9BQ37429706-0472D544-6E40-46AE-B434-C154C68939E6Q37838684-ECEF8333-EE50-4435-BA51-DF43D2F6CB36Q38116768-567BC5C1-5DCE-41F4-A97B-C639C4D42D1EQ38164139-621EF16E-F6E0-42F9-9A7B-6D5F0E1D9644Q38202556-B450A4C3-D77D-4A60-A66A-7FFFE9EF7412Q38898974-5DB0A95A-BA59-43EB-B505-14874710FB6FQ38915685-72CB182F-66E0-4331-A49E-B6F37970C60EQ39033624-5786DA6F-3C3C-4639-94A8-F02BDF082440Q39144692-D13FED30-D902-4F68-B199-5456F288F72CQ39262510-6548830E-FA62-4CA0-9DA2-1D08F86F445AQ39355884-9EA4F26A-2158-4991-9C5B-AB04466B5847Q39697762-A825B355-419D-4538-BF20-55AE5E354536Q40056019-277E0049-CFB7-4C84-B4FA-904A47C0BFA1Q41948418-95F641F1-0896-46A2-A8A5-3D9B0221078FQ42052945-BDC12A8D-1B0B-4FBC-90D7-43EFA0522CFFQ42427927-36F903F7-9BD6-47F1-81A4-B5CFE486E16D
P2860
Targeting signal transducer and activator of transcription signaling pathway in leukemias.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting signal transducer an ...... ignaling pathway in leukemias.
@en
Targeting signal transducer an ...... ignaling pathway in leukemias.
@nl
type
label
Targeting signal transducer an ...... ignaling pathway in leukemias.
@en
Targeting signal transducer an ...... ignaling pathway in leukemias.
@nl
prefLabel
Targeting signal transducer an ...... ignaling pathway in leukemias.
@en
Targeting signal transducer an ...... ignaling pathway in leukemias.
@nl
P2860
P356
P1476
Targeting signal transducer and activator of transcription signaling pathway in leukemias
@en
P2093
Heinz Baumann
Meir Wetzler
P2860
P304
P356
10.1200/JCO.2008.21.3264
P407
P577
2009-08-10T00:00:00Z